Kirsten joins Alzheimer’s Research UK to support dementia research
In the UK nearly one million people are living with dementia, and it is one of the leading causes of death.
According to Alzheimers UK, 1,366 residents in East Renfrewshire are living with dementia, perhaps one third of them undiagnosed.
Advertisement
Hide AdAdvertisement
Hide AdNot only does dementia cause harm and heartbreak, it also places a huge strain on health and social care system.
The economic cost to the UK of caring for people with dementia is estimated to grow from £24bn in 2014 to £59bn by 2050.
Ms Oswald was one of many MPs to meet with representatives from Alzheimer’s Research UK, the country’s leading dementia research charity, as well as people impacted by the condition.
Last July, Ms Oswald and her staff team received the first Digital Dementia Friends training session from East Renfrewshire dementia advisor, Nicola Kennedy.
Advertisement
Hide AdAdvertisement
Hide AdMs Oswald said: “I was delighted to join Alzheimer’s Research UK to show my support for their work to help find preventions, treatments and, one day, a cure for dementia.
“It is estimated that over 1,300 people are living with dementia in East Renfrewshire, with a devastating impact on them and their families.
“It is vital that we increase investment in dementia research to help make the progress needed to end the fear, harm and heartbreak caused by dementia.
“It is also vital that we do what we can to create Dementia Friendly Communities, which is why I was so pleased to have my whole staff team take part in Dementia Friendly training provided by Alzheimer Scotland.”
Advertisement
Hide AdAdvertisement
Hide AdDavid Thomas, Head of Policy at Alzheimer’s Research UK, said:
“A big thank you to Kirsten for taking the time to join us and support dementia research during World Alzheimer’s Month.
“Dementia is one of the biggest global health crises we face. In 2019, the Government made a manifesto promise to double funding for dementia research to £160m a year and speed up progress in clinical trials. Now is the time to deliver on this pledge.”